Clinical Trials Logo

Hepatitis C, Chronic clinical trials

View clinical trials related to Hepatitis C, Chronic.

Filter by:

NCT ID: NCT01525628 Completed - Clinical trials for Hepatitis C, Chronic

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Start date: April 2012
Phase: Phase 1
Study type: Interventional

To evaluate the drug-drug interactions between BI 201335 and BI 207127 as well as their combined effect on CYP probe drug substrates and on tenofovir and raltegravir in treatment naive or prior treatment relapse patients with chronic hepatitis C infection.

NCT ID: NCT01523990 Completed - Healthy Clinical Trials

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

Start date: October 2011
Phase: Phase 1
Study type: Interventional

A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients

NCT ID: NCT01516918 Completed - Clinical trials for Chronic Hepatitis C Virus

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Start date: February 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of a quadruple regimen (VX-222, telaprevir, pegylated interferon, and ribavirin)in subjects with hepatitis C with cirrhosis.

NCT ID: NCT01514890 Completed - Chronic Hepatitis C Clinical Trials

French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin

CUPIC
Start date: February 2011
Phase: N/A
Study type: Observational

The purpose fo the study is to evaluate the efficacy defined by the sustained virological response (SVR), in patients with compensated cirrhosis treated with PEG-IFN, RBV and telaprevir or boceprevir in the French Early Access Program for the use of protease inhibitors or after the approval of these drugs through the the marketing authorization.

NCT ID: NCT01513941 Completed - Chronic Hepatitis C Clinical Trials

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

INSIGHT
Start date: April 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both chronic hepatitis C virus (HCV-1) and human immunodeficiency virus (HIV-1).

NCT ID: NCT01511432 Completed - Chronic Hepatitis C Clinical Trials

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.

NCT ID: NCT01509391 Completed - Liver Cirrhosis Clinical Trials

Keyhole Limpet Hemocyanin in Chronic Hepatitis C

IM1
Start date: January 2012
Phase: N/A
Study type: Interventional

In this study the investigators examine the safety and efficacy of Keyhole-limpet-hemocyanin in patients with chronic hepatitis c infection and liver cirrhosis. The investigators hypothesize that administration of keyhole-limpet-hemocyanin reduces the viral load in patients infected with hepatitis c.

NCT ID: NCT01508156 Completed - Clinical trials for Hepatitis C, Chronic

Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No formal hypotheses will be tested.

NCT ID: NCT01508130 Completed - Clinical trials for Hepatitis C, Chronic

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Start date: January 2012
Phase: N/A
Study type: Observational

This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1. Patients receiving pegylated interferon (e.g. Pegasys) and ribavirin plus either telaprevir or boceprivir in accordance with local standard of care and US labeling will be followed for the duration of their treatment and for up to 24 weeks post-treatment.

NCT ID: NCT01500616 Completed - Clinical trials for Hepatitis C, Chronic

Telaprevir Open-Label Study in Co-Infected Patients

Start date: June 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg‑IFN‑alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated cirrhosis who are not eligible for enrollment into an ongoing clinical study of telaprevir.